Influence of catalyst support characteristics and functionalization on the catalytic activity of Pt-Ru for PEM fuel cells

Pt-Ru electrocatalysts supported on carbon xerogels and ordered mesoporous carbons were synthesized by reduction with formate ions (SFM method). Chemical and heat treatments were applied to modified the surface chemistry of original carbon supports. Physical characterization of the catalysts was performed using X-ray dispersive energy (EDX) and X-ray diffraction (XRD) techniques, while the electrochemical activity towards methanol oxidation was studied by cyclic voltammetry (CV). Pt-Ru catalysts with nominal metal content (20 wt.%) and atomic ratios (Pt:Ru 1:1) were successfully synthesized on the different supports. Higher methanol oxidation current densities were obtained for those supports with a higher content of surface oxygen groups. Gas diffusion electrode and membrane-electrode-assembly preparation allowed an in-house built of a direct methanol fuel monocell for the evaluation of the catalysts performance. Polarization curves were measured confirming the results obtained in a three electrodes electrochemical cell by CV. Normalized power curves per weight of Pt are discussed in terms of the significant impact on noble metal loading and attained cell maximum power, in comparison with results obtained with a commercial catalyst

Pt-Ru Catalysts supported on mesoporous carbons for polymer electrolyte membrane fuel cells

Pt-Ru electrocatalysts supported on xerogels and CMK-3 ordered mesoporous carbons were synthesized by reduction with formate ions (SFM method). Some of the carbon supports were chemically treated with HNO3 in order to generate oxygen groups on the surface, while other supports were heat treated. Physical characterization of the catalyst was obtained using X-ray dispersive energy (EDX) and X-ray diffraction (XRD) techniques. Results showed that Pt-Ru catalysts with similar metal content (20%) and atomic ratios (Pt:Ru 1:1) were obtained. The electrochemical activity was studied by cyclic voltammetry and chronoamperometry. Higher methanol oxidation current densities were found for catalyst deposited on chemically treated supports. Electrode preparation and MEA assembly allowed an in-house built direct methanol fuel to be fitted with the synthesized catalysts and supports in order to assess their performance. Cell and reactants were conditioned by a direct methanol test station. Polarisation curves were measured and confirmed data obtained by voltammetry, regarding the effect of heat treatment of the carbon support. Normalised power curves per weight of catalyst are discussed in terms of the significant impact on noble metal loading and attained cell maximum power, in comparison with results obtained with a commercial catalyst

Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12

Despite the efficacy of IL-12 in cancer experimental models, clinical trials with systemic recombinant IL-12 showed unacceptable toxicity related to endogenous IFNgamma production. We report that systemic administration of a recombinant adenovirus encoding IL-12 (AdCMVmIL-12) has a dramatically different survival outcome in a number of mouse pure strains over a wide range of doses. For instance at 2.5 x 10(9) p.f.u., systemic AdCMVmIL-12 killed all C57BL/6 mice but spared all BALB/c mice. Much higher IFNgamma concentrations in serum samples of C57BL/6 than in those from identically treated BALB/c were found. Causes for heterogeneous toxicity can be traced to differences among murine strains in the levels of gene transduction achieved in the liver, as assessed with adenovirus coding for reporter genes. In accordance, IL-12 serum concentrations are higher in susceptible mice. In addition, sera from C57BL/6 mice treated with AdCMVmIL-12 showed higher levels of IL-18, a well-known IFNgamma inducer. Interestingly, lethal toxicity in C57BL/6 mice was abolished by administration of blocking anti-IFNgamma mAbs and also by simultaneous depletion of T cells, NK cells, and macrophages. These observations together with the great dispersion of IFNgamma produced by human PBMCs upon in vitro stimulation with IL-12, or infection with recombinant adenovirus encoding IL-12, suggest that patients might also show heterogeneous degrees of toxicity in response to IL-12 gene transfer

Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12

OBJECTIVE: Injection of dendritic cells (DC) engineered with recombinant adenoviral vectors to produce interleukin-12 (IL-12) inside experimental murine tumors frequently achieves complete regressions. In such a system the function of CD8(+) T cells has been shown to be an absolute requirement, in contrast to observations made upon depletion of CD4(+) T cells, which minimally affected the outcome. The aim of this work was to study the possible involvement of natural killer (NK) cells in this setting. MATERIALS, METHODS, AND RESULTS: Depletions with anti-AsialoGM1 antiserum showed only a small decrease in the proportion of complete regressions obtained that correlated with induction of NK activities in lymphatic tissues into which DC migrate, whereas combined depletions of CD4(+) and NK cells completely eliminated the antitumor effects. Likewise in vivo neutralization of interferon-gamma (IFN-gamma) also eliminated those therapeutic effects. Trying to define the cellular role played by NK cells in vivo, it was observed that injection of cultured DC inside the spleen of T- and B-cell-deficient (Rag1(-/-)) mice induced upregulation of NK activity only if DC had been adenovirally engineered to produce IL-12. In addition, identically transfected fibroblasts also activated NK cells, indicating that IL-12 transfection was the unique requirement. Equivalent human DC only activated in vitro the cytolytic and cytokine-secreting functions of autologous NK cells if transfected to express human IL-12. CONCLUSIONS: Overall, these results point out an important role played by NK cell activation in the potent immunotherapeutic effects elicited by intratumoral injection of IL-12--secreting DC and that NK activation under these conditions is mainly, if not only, dependent on IL-12

La infusión de linfocitos efectores autólogos en combinación con rituximab de mantenimiento

SP-004 Introducción: La combinación de anticuerpos monoclonales anti CD20 con varios regimenes de quimioterapia se considera el tratamiento estándar en pacientes con linfoma folicular (LF). A pesar de los buenos resultados de este tratamiento, un porcentaje importante de los pacientes no se beneficia de esta terapia ensombreciendo de manera considerable su pronóstico. Nuestra hipótesis es que el tratamiento con una suspensión de linfocitos efectores autólogos expandidos ex vivo (células LAK) podría potenciar el efecto biológico del tratamiento con rituximab (R) mediante el incremento de la actividad ADCC. Investigamos la toxicidad y eficacia de dicho tratamiento con un ensayo clínico fase II. Métodos: Entre 2010 y 2012 se reclutaron 20 pacientes con LF en respuesta tras una primera línea de tratamiento con R-CHOP. El objetivo primario de este ensayo, multicéntrico, prospectivo y de un solo brazo fue evaluar la seguridad y eficacia de la infusión de células LAK (administradas cuatrimestralmente en los ciclos pares de R) en combinación con la pauta estándar de R de mantenimiento bimestral durante 2 años. La producción de células LAK se realizó a partir de células de sangre periférica extraídas en los ciclos impares de R para aislar células mononucleadas y estimularlas y expandirlas en cultivo con interleukina-2 durante 8 semanas. Uno de los objetivos secundarios del ensayo fue la evaluación de los fenotipos celulares y de la potencia biológica de las células LAK midiendo su actividad citotóxica. Este ensayo está registrado en ClinicalTrials.gov con número NCT01329354 Resultados: Se registraron 29 eventos adversos (EA) relacionados con la infusión de las células LAK. Las artralgias y las ..